Telix's EPS Forecasts Rise Around 9% for Fiscal 2027, Around 21% for Fiscal 2028 After Glioma Drug Approval, Jefferies Says

MT Newswires Live

昨天

Telix Pharmaceuticals (ASX:TLX) earnings per share (EPS) forecasts rose by around 9% in fiscal 2027 and around 21% in fiscal 2028 after securing US Food and Drug Administration (FDA) approval for its new drug application for Pixclara, according to a Monday note by Jefferies.

Major changes to the forecasts include an assumption of US reimbursement approval and the beginning of material US sales from the start of fiscal 2027's second half.

Pixclara is an amino acid positron emission tomography (PET) drug for imaging glioma, a type of brain tumor.

It is indicated for use with PET to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and paediatric patients one month of age and older.

The brokerage assigned a buy rating to Telix with a raised price target of AU$30 per share from AU$29.30.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2667487616"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2667487616\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2667487616?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-15 13:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2667487616","market":"hk","top_or_hot":-1,"title":"Telix's EPS Forecasts Rise Around 9% for Fiscal 2027, Around 21% for Fiscal 2028 After Glioma Drug Approval, Jefferies Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a> (ASX:TLX) earnings per share (EPS) forecasts rose by around 9% in fiscal 2027 and around 21% in fiscal 2028 after securing US Food and Drug Administration (FDA) approval for its new drug application for Pixclara, according to a Monday note by Jefferies.</p><p>Major changes to the forecasts include an assumption of US reimbursement approval and the beginning of material US sales from the start of fiscal 2027's second half.</p><p>Pixclara is an amino acid positron emission tomography (PET) drug for imaging glioma, a type of brain tumor.</p><p>It is indicated for use with PET to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and paediatric patients one month of age and older.</p><p>The brokerage assigned a buy rating to Telix with a raised price target of AU$30 per share from AU$29.30.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Telix's EPS Forecasts Rise Around 9% for Fiscal 2027, Around 21% for Fiscal 2028 After Glioma Drug Approval, Jefferies Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTelix's EPS Forecasts Rise Around 9% for Fiscal 2027, Around 21% for Fiscal 2028 After Glioma Drug Approval, Jefferies Says\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-09-15 13:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a> (ASX:TLX) earnings per share (EPS) forecasts rose by around 9% in fiscal 2027 and around 21% in fiscal 2028 after securing US Food and Drug Administration (FDA) approval for its new drug application for Pixclara, according to a Monday note by Jefferies.</p><p>Major changes to the forecasts include an assumption of US reimbursement approval and the beginning of material US sales from the start of fiscal 2027's second half.</p><p>Pixclara is an amino acid positron emission tomography (PET) drug for imaging glioma, a type of brain tumor.</p><p>It is indicated for use with PET to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and paediatric patients one month of age and older.</p><p>The brokerage assigned a buy rating to Telix with a raised price target of AU$30 per share from AU$29.30.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2667487616","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2667487616","pubTimestamp":1789450283,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Telix Pharmaceuticals  earnings per share  forecasts rose by around 9% in fiscal 2027 and around 21% in fiscal 2028 after securing US Food and Drug Administration  approval for its new drug application for Pixclara, according to a Monday note by Jefferies.Major changes to the forecasts include an assumption of US reimbursement approval and the beginning of material US sales from the start of fiscal 2027's second half.Pixclara is an amino acid positron emission tomography  drug for imaging glioma, a type of brain tumor.It is indicated for use with PET to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and paediatric patients one month of age and older.The brokerage assigned a buy rating to Telix with a raised price target of AU$30 per share from AU$29.30.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","PET.AU":"PHOSLOCK ENVIRONMENTAL TECHN","TLX.AU":"TELIX PHARMACEUTICALS LTD","BK7047":"环境与设施服务"},"translate_title":"杰富瑞表示，胶质瘤药物获批后，Telix 2027 财年每股收益预测将增长约 9%，2028 财年每股收益预测将增长约 21%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX.AU":1,"PET.AU":1},"content_text":"Telix Pharmaceuticals (ASX:TLX) earnings per share (EPS) forecasts rose by around 9% in fiscal 2027 and around 21% in fiscal 2028 after securing US Food and Drug Administration (FDA) approval for its new drug application for Pixclara, according to a Monday note by Jefferies.Major changes to the forecasts include an assumption of US reimbursement approval and the beginning of material US sales from the start of fiscal 2027's second half.Pixclara is an amino acid positron emission tomography (PET) drug for imaging glioma, a type of brain tumor.It is indicated for use with PET to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and paediatric patients one month of age and older.The brokerage assigned a buy rating to Telix with a raised price target of AU$30 per share from AU$29.30.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}